The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $74.00 expecting SWTX to rise to within 12 months (a possible 79.83% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for SpringWorks Therapeutics (NASDAQ:SWTX) was provided by HC Wainwright & Co., and SpringWorks Therapeutics reiterated their buy rating.

There is no last upgrade for SpringWorks Therapeutics

There is no last downgrade for SpringWorks Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.

While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a reiterated with a price target of $74.00 to $74.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $41.15, which is out of the analyst’s predicted range.